T. Asakawa

13.0k total citations · 1 hit paper
59 papers, 936 citations indexed

About

T. Asakawa is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Electrical and Electronic Engineering. According to data from OpenAlex, T. Asakawa has authored 59 papers receiving a total of 936 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Electrical and Electronic Engineering. Recurrent topics in T. Asakawa's work include Lung Cancer Treatments and Mutations (6 papers), Gaze Tracking and Assistive Technology (6 papers) and Tactile and Sensory Interactions (6 papers). T. Asakawa is often cited by papers focused on Lung Cancer Treatments and Mutations (6 papers), Gaze Tracking and Assistive Technology (6 papers) and Tactile and Sensory Interactions (6 papers). T. Asakawa collaborates with scholars based in Japan, United States and Germany. T. Asakawa's co-authors include Taro Shibata, Kenji Suzuki, Kanji Nagai, Teruaki Koike, Hisao Asamura, Haruhiko Fukuda, Tetsuya Mitsudomi, Masahiro Tsuboi, Masahiko Kusumoto and Harubumi Kato and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and British Journal of Cancer.

In The Last Decade

T. Asakawa

51 papers receiving 914 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201)

2011 464 citations Kenji Suzuki, Teruaki Koike et al. Journal of Thoracic Oncology profile →

Peers

Countries citing papers authored by T. Asakawa

Since Specialization

Citations

This map shows the geographic impact of T. Asakawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by T. Asakawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites T. Asakawa more than expected).

Fields of papers citing papers by T. Asakawa

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by T. Asakawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by T. Asakawa. The network helps show where T. Asakawa may publish in the future.

Co-authorship network of co-authors of T. Asakawa

This figure shows the co-authorship network connecting the top 25 collaborators of T. Asakawa. A scholar is included among the top collaborators of T. Asakawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with T. Asakawa. T. Asakawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Planning and Implementing Master Protocol Trials in Japan: Key Considerations of the Japanese Guideline 2024 ·Clinical Pharmacology & Therapeutics ·Akihiro Hirakawa, T. Asakawa, (unknown), (unknown), (unknown), Hitomi Sumiyoshi Okuma, (unknown), Yosuke Shimizu, (unknown), (unknown), Hiroyuki Sato, Yukari Uemura	0
2	Summary Report of a Public Workshop: Case Studies of Multi‐Regional Clinical Trial Incorporating Concept of the ICH E17 Guideline 2024 ·Clinical Pharmacology & Therapeutics ·Nobuko Matsushima, (unknown), (unknown), Ryuta Nakamura, Shuhei Kaneko, T. Asakawa, (unknown), (unknown), (unknown), (unknown), Yukio Ando	1
3	FGFR blockade inhibits targeted therapy-tolerant persister in basal FGFR1- and FGF2-high cancers with driver oncogenes 2023 ·npj Precision Oncology ·Koh Furugaki, (unknown), (unknown), (unknown), T. Asakawa, Yasushi Yoshimura, (unknown)	13
4	Effects of interventions on life‐space mobility for community‐dwelling older adults: A systematic review and meta‐analysis 2023 ·Geriatrics and gerontology international ·(unknown), (unknown), (unknown), T. Asakawa, (unknown)	1
5	Effects of Rehabilitative Intervention for Augmenting Cough Function in Patients with Multiple System Atrophy 2023 ·Progress in Rehabilitation Medicine ·T. Asakawa, Mieko Ogino, Naomi Tominaga, (unknown), (unknown), Wataru Kakuda	0
6	Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study 2023 ·Liver Cancer ·Masatoshi Kudo, Kaoru Tsuchiya, Yu‐Yun Shao, Richard S. Finn, Peter R. Galle, Michel Ducreux, Ann‐Lii Cheng, Tatsuya Yamashita, Hironori Koga, (unknown), Kyoko Yamada, T. Asakawa, Yuki Nakagawa, Masafumi Ikeda	13
7	The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study 2020 ·Breast Cancer Research and Treatment ·Masato Takahashi, Shoichiro Ohtani, Shigenori E. Nagai, Seiki Takashima, Miki Yamaguchi, Michiko Tsuneizumi, Yoshifumi Komoike, Tomofumi Osako, Yoshinori Ito, Masahiko Ikeda, Kazushige Ishida, Takahiro Nakayama, Tsutomu Takashima, T. Asakawa, Sho Matsumoto, Daisuke Shimizu, Norikazu Masuda	7
8	Pertuzumab plus trastuzumab and chemotherapy for Japanese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subgroup analysis of the JACOB trial 2019 ·International Journal of Clinical Oncology ·Kohei Shitara, Hiroki Hara, Takaki Yoshikawa, Kazumasa Fujitani, Tomohiro Nishina, Ayumu Hosokawa, T. Asakawa, (unknown), Kei Muro	11
9	P3.02c-038 First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naïve Patients with Advanced NSCLC: A Phase III Clinical Program 2017 ·Journal of Thoracic Oncology ·Federico Cappuzzo, Martin Reck, Vassiliki A. Papadimitrakopoulou, Robert M. Jotte, Howard West, Tony Mok, Alan Sandler, Simonetta Mocci, Shelley Coleman, T. Asakawa, Mark A. Socinski	1
10	PS01.53: First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program 2016 ·Journal of Thoracic Oncology ·Robert M. Jotte, Mark A. Socinski, Martin Reck, Vassiliki A. Papadimitrakopoulou, Howard West, Tony Mok, Alan Sandler, Simonetta Mocci, Shelley Coleman, T. Asakawa, Federico Cappuzzo	4
11	MEG Frequency Analysis Depicts the Impaired Neurophysiological Condition of Ischemic Brain 2016 ·PLoS ONE ·Shinichi Sakamoto, Hidetoshi Ikeda, Naohiro Tsuyuguchi, Takehiro Uda, (unknown), T. Asakawa, Yasuhiro Haruta, Hideki Nishiyama, (unknown), Hajime Kamada, Kenji Ohata, Yukio Miki	2
12	Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy 2016 ·Annals of Oncology ·Martin Reck, Vassiliki A. Papadimitrakopoulou, Federico Cappuzzo, Robert M. Jotte, Tony Mok, A. Sandler, Daniel Waterkamp, (unknown), T. Asakawa, Mark A. Socinski	4
13	A Continual Reassessment Method that Adaptively Changes the Prior Distribution According to the Initial Cohort Observation 2012 ·Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics ·T. Asakawa, (unknown), Chikuma Hamada	0
14	An electric music baton system using a haptic interface for visually disabled persons 2012 ·Society of Instrument and Control Engineers of Japan ·T. Asakawa, (unknown)	7
15	2P1-D09 Study of Improvement of Response Time Using Haptic Interface(Universal Design & Robot Therapy) 2011 ·The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec) ·T. Asakawa, (unknown), (unknown), (unknown)	1
16	A Prospective Radiological Study of Thin-Section Computed Tomography to Predict Pathological Noninvasiveness in Peripheral Clinical IA Lung Cancer (Japan Clinical Oncology Group 0201) breakdown → 2011 ·Journal of Thoracic Oncology ·Kenji Suzuki, Teruaki Koike, T. Asakawa, Masahiko Kusumoto, Hisao Asamura, Kanji Nagai, Hirohito Tada, Tetsuya Mitsudomi, Masahiro Tsuboi, Taro Shibata, Haruhiko Fukuda, Harubumi Kato	464
17	A Detection System of Location and Direction Angle by a RF Tag Reader Using a Rotary Antenna 2008 ·Journal of Robotics and Mechatronics ·T. Asakawa, (unknown), (unknown)	5
18	Randomised phase III trial of carboplatin plus etoposide vs split doses of cisplatin plus etoposide in elderly or poor-risk patients with extensive disease small-cell lung cancer: JCOG 9702 2007 ·British Journal of Cancer ·Hiroaki Okamoto, Kenji Watanabe, Hiroshi Kunikane, Akira Yokoyama, S. Kudoh, T. Asakawa, Taro Shibata, Hideo Kunitoh, Tomohiro Tamura, Nagahiro Saijo	148
19	2P2-A22 Measurement of Location and Direction Using IC Tags Applying to Indoor Navigation 2006 ·The Proceedings of JSME annual Conference on Robotics and Mechatronics (Robomec) ·(unknown), Gang Wang, T. Asakawa, (unknown), (unknown)	2
20	CLINICAL STUDY ON THE CARBOHYDRATE METABOLISM AND PANCREATIC ENDOCRINE FUNCTION AFTER ESOPHAGECTOMY 1982 ·The Japanese Journal of Gastroenterological Surgery ·(unknown), Sei Shiraha, (unknown), (unknown), T. Asakawa, (unknown), (unknown), (unknown), (unknown), Hiroya Umemura, Takeshi Kuyama	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact